Efficacy and Safety of Roflumilast in Korean Patients with COPD

PURPOSE: Roflumilast is the only oral phosphodiesterase 4 inhibitor approved to treat chronic obstructive pulmonary disease (COPD) patients [post-bronchodilator forced expiratory volume in 1 second (FEV(1)) <50% predicted] with chronic bronchitis and a history of frequent exacerbations. This stud...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Yonsei Med J
Glavni autori: Lee, Jae Seung, Hong, Yoon Ki, Park, Tae Sun, Lee, Sei Won, Oh, Yeon-Mok, Lee, Sang-Do
Format: Artigo
Jezik:Inglês
Izdano: Yonsei University College of Medicine 2016
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4951470/
https://ncbi.nlm.nih.gov/pubmed/27189287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3349/ymj.2016.57.4.928
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items